

James J. Lee, Esq. (Nevada Bar No. 1909)  
james@leelitigate.com  
LEGAL OFFICES OF JAMES J. LEE  
2620 Regatta Drive #102  
Las Vegas, NV 89128  
Telephone: 702.521.4377 (cell)  
Telephone: 702.664.6545 (office)  
Facsimile: 702.946.1115

Wendy R. Fleishman (NY Bar No. WF 3017)  
(Admission pro hac vice anticipated)  
wfleishman@lchb.com  
LIEFF CABRASER HEIMANN & BERNSTEIN, LLP  
250 Hudson Street, 8th Floor  
New York, NY 10013-1413  
Telephone: 212.355.9500  
Facsimile: 212.355.9592

Fabrice N. Vincent (CA Bar No. 160780)  
(Admission pro hac vice anticipated)  
fvincent@lchb.com  
Lexi J. Hazam (CA Bar No. 224457)  
(Admission pro hac vice anticipated)  
lhazam@lchb.com  
LIEFF CABRASER HEIMANN & BERNSTEIN, LLP  
275 Battery Street, 29th Floor  
San Francisco, CA 94111-3339  
Telephone: 415.956.1000  
Facsimile: 415.956.1008

*Attorneys for Plaintiffs*

UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEVADA

DARIUS MEDLEY and CHAKOYA  
ROBINSON, individually and on behalf of  
their minor child KM as his natural and  
legal guardians,

Plaintiffs,

v.

ABBOTT LABORATORIES, INC.,

Defendant.

Case No. \_\_\_\_\_

**CIVIL COMPLAINT FOR DAMAGES**

**JURY TRIAL DEMANDED**

1 Plaintiffs Darius Medley and ChaKoya Robinson bring this action on behalf of their minor  
2 son KM and complain of Defendant Abbott Laboratories, Inc., as follows, based upon  
3 information and belief, their counsels' investigation, and personal knowledge.

4 **I. INTRODUCTION**

5 1. This is an action to redress the serious and grievous injuries suffered by infant  
6 KM, who has spent the majority of his almost four years of life fighting a horrific disease caused  
7 by Defendant's cow-based infant formula and fortifier Similac Neosure ("NeoSure"). Necrotising  
8 enterocolitis (NEC) is a potentially fatal disease that largely affects low birth weight babies who  
9 are fed cow-based formula. KM, a prematurely born, low birth weight baby, was fed NeoSure and  
10 developed NEC shortly thereafter.

11 2. Plaintiffs Darius Medley and ChaKoya Robinson bring claims against Defendant  
12 Abbott Laboratories, Inc., arising from Defendant's negligent, willful, and wrongful conduct in  
13 connection with the design, development, manufacture, testing, packaging, promotion, marketing,  
14 distribution, labeling, and/or sale of NeoSure.

15 **II. THE PARTIES**

16 3. KM ("Baby KM") was born prematurely at 23 weeks and 5 days on July 6, 2018,  
17 at Sunrise Hospital and Medical Center in Las Vegas, Nevada. He weighed 1 pound, 1 ounce at  
18 birth and was therefore by definition a low birth weight infant. Baby KM developed NEC within  
19 days of being fed NeoSure while he was in the neonatal intensive care unit (NICU) at Sunrise  
20 Hospital.

21 4. Plaintiffs Darius Medley and ChaKoya Robinson are the natural parents and  
22 guardians of Baby KM, and they are all residents of Nevada.

23 5. Defendant Abbott Laboratories, Inc., ("Abbott") is a corporation incorporated  
24 under the laws of Illinois with its principal place of business in Abbott Park, Illinois.

25 6. Defendant Abbott manufactures, designs, formulates, prepares, tests, provides  
26 instructions, markets, labels, packages, places into the stream of commerce, and sells NeoSure in  
27 all fifty states, including Nevada, and is a "product seller" under Nevada law.  
28

1 **III. JURISDICTION AND VENUE**

2 7. This Court has jurisdiction under 28 U.S.C. § 1332(d) because complete diversity  
3 exists between Plaintiffs, each citizens of Nevada, and Defendant Abbott, a citizen of Illinois, and  
4 the matter in controversy, exclusive of interest and costs, exceeds \$75,000.

5 8. This Court has personal jurisdiction over Defendant Abbott because Abbott  
6 markets, promotes, distributes, and sells NeoSure in Nevada, and Plaintiffs' claims arise out of  
7 Abbott's contacts with Nevada.

8 9. Venue is proper in this district under 28 U.S.C. § 1391(b) because Plaintiffs reside  
9 in this district, Baby KM consumed NeoSure in this district, and therefore a substantial part of the  
10 events or omissions giving rise to Plaintiffs' claims occurred in this district.

11 **IV. BACKGROUND**

12 **A. The Science**

13 10. Scientific research has demonstrated strong links between cow-based infant  
14 formula like NeoSure and NEC in premature infants.

15 11. More than thirty years ago, in 1990, a prospective multi-center study on 926  
16 preterm infants found that NEC was 6 to 10 times more common in exclusively formula-fed  
17 babies than in those fed breast milk alone, and three times more common than in those who  
18 received formula plus breast milk. Lucas A, Cole T. Breast milk and neonatal necrotising  
19 enterocolitis. Lancet 1990; 336: 1519–1523.

20 12. A study published in 2010 established that when premature babies were fed an  
21 exclusive diet of mother's milk, donor milk, and/or human milk fortifier, they were 90 percent  
22 less likely to develop surgical NEC. Sullivan, S., et al., An Exclusively Human Milk-Based Diet  
23 Is Associated with a Lower Rate of Necrotising Enterocolitis than a Diet of Human Milk and  
24 Bovine Milk-Based Products. Journal of Pediatrics 2010; 156:562-7.

25 13. In 2011, the U.S. Surgeon General published a report titled "The Surgeon  
26 General's Call to Action to Support Breastfeeding," warning that, "[f]or vulnerable premature  
27 infants, formula feeding is associated with higher rates of [NEC]." U.S. Department of Health and  
28

1 Human Services. The Surgeon General's Call to Action to Support Breastfeeding. Washington,  
2 DC: U.S. Department of Health and Human Services, Office of the Surgeon General; 2011, p. 1.

3 14. In 2012, the American Academy of Pediatrics issued a policy statement that all  
4 premature infants should be fed exclusively a human milk diet because of the risk of NEC  
5 associated with the consumption of cow-based formula like NeoSure. The Academy stated that  
6 "[t]he potent benefits of human milk are such that all preterm infants should receive human milk.  
7 ... If the mother's own milk is unavailable ... pasteurized donor milk should be used."  
8 Breastfeeding and the Use of Human Milk. Pediatrics 2012; 129:e827-e841.

9 15. A study published in 2013 showed that all 104 premature infants participating in  
10 the study receiving exclusively a human-milk based diet exceeded targeted growth standards in  
11 height and weight (weight and head circumference). The authors concluded that "this study  
12 provides data showing that infants can achieve and mostly exceed targeted growth standards  
13 when receiving an exclusive human milk-based diet." Hair, A, et al., Human milk supports  
14 adequate growth in infants  $\leq 1250$  grams birthweight. BMC Research Notes 2013, 6-459. Thus,  
15 inadequate growth was shown to be no reason for feeding cow-based formula.

16 16. Another study published in 2013 reported, "This is the first randomized trial in  
17 [extremely premature] infants of exclusive [human Milk] vs. [preterm formula]. The significantly  
18 shorter duration of [total parenteral nutrition] and lower rate of surgical NEC support major  
19 changes in the strategy to nourish [extremely premature] infants in the NICU." Cristofalo, E.A., et  
20 al., Exclusive Human Milk vs Preterm formula: Randomized Trial in Extremely Preterm Infants.  
21 J Pediatr 2013 Dec; 163(6): 1592-1595.

22 17. "It is well established that the risk is increased by the administration of infant  
23 formula and decreased by the administration of breast milk." Good, Misty, et al., Evidence Based  
24 Feeding Strategies Before and After the Development of Necrotizing Enterocolitis. Expert Rev  
25 Clin Immunol. 2014 July; 10 (7): 875-884. The same study noted, "NEC affects 7-12% of  
26 preterm infants weighing less than 1500 grams, and the frequency of disease appears to be either  
27 stable or rising in several studies. The typical patient who develops NEC is a premature infant  
28 who displays a rapid progression from mild feeding intolerance to systemic sepsis, and up to 30%

1 of infants will die from this disease.” (Internal citations omitted.) Further, “[a] wide variety of  
2 feeding practices exist on how to feed the premature infant in the hopes of preventing [NEC]. ...  
3 The exclusive use of human breast milk is recommended for all premature infants and is  
4 associated with a significant decrease in the incidence of NEC.” (Internal citations omitted.)

5 18. Yet another study published in 2014 reported, “An exclusive human milk diet,  
6 devoid of [cow milk]-containing products was associated with lower mortality and morbidity in  
7 [extremely premature] infants without compromising growth and should be considered as an  
8 approach to nutritional care of these infants.” Abrams, Steven, et al. Greater Mortality and  
9 Morbidity in Extremely Preterm Infants Fed a Diet Containing Cow Milk Protein Products.  
10 Breastfeeding Medicine. 2014, Nov. 4, 9(6):281-286.

11 19. A 2016 study supported previous findings that an exclusive human milk diet in  
12 extremely premature infants dramatically decreased the incidence of both medical and surgical  
13 NEC. This was the first study to compare rates of NEC after a feeding protocol implementation at  
14 multiple institutions with multiple years of follow-up using an exclusive human milk diet, and  
15 was a very large study. The authors concluded, “[T]he use of an exclusive [human milk] diet is  
16 associated with significant benefits for extremely premature infants” and, “while evaluating the  
17 benefits of using an exclusive [human milk]-based protocol, it appears that there were no feeding-  
18 related adverse outcomes.” Hair, et al., Beyond Necrotizing Enterocolitis Prevention: Improving  
19 Outcomes with an Exclusive Human Milk-Based Diet. Breastfeeding Medicine 2016, 11-2.

20 20. A study published in 2017 reported, “[Human milk] has been acknowledged as the  
21 best source of nutrition for preterm infants and those at risk for NEC. Two [randomized clinical  
22 trials] on preterm infants weighing between 500 and 1250 g at birth compared the effect of bovine  
23 milk-based preterm infant formula to [mother or donor milk] on the incidence of NEC. Both trials  
24 found that an exclusive [human milk] diet results in a lower incidence of NEC.”

25 21. A systematic review that evaluated the effect of cow milk-based formula like  
26 NeoSure on health outcomes for preterm infants also determined that cow milk-based formula  
27 significantly increases the risk of NEC. Shulhan, Jocelyn, et al. Current Knowledge of  
28

1 Necrotizing Enterocolitis in Preterm Infants and the Impact of Different Types of Enteral  
2 Nutrition Products. ASN. ADV Nutr 2017; 8:8—0-91.

3 **B. The Marketing**

4 22. Notwithstanding strong scientific and medical evidence establishing the serious  
5 danger that cow-based formula like NeoSure poses for premature infants like Baby KM,  
6 Defendant Abbott has marketed its cow-based products as an equally safe alternative to breast  
7 milk, and indeed has promoted its products as necessary for additional nutrition and growth.  
8 Abbott has specifically marketed NeoSure as necessary to the growth and development of  
9 premature infants, when in fact its products pose a known and substantial risk to these babies.

10 23. Defendant Abbott has attempted to “hook” parents on formula by offering free  
11 samples and other blandishments in baskets given to parents in hospitals and medical clinics. The  
12 goal is to create brand loyalty and the appearance of “medical blessing” so that parents continue  
13 to use NeoSure to feed their babies after they leave the NICU, at great expense to the parents, and  
14 substantial profit to Abbott.

15 24. Defendant Abbott’s practice of trying to get parents to choose formula over breast  
16 milk goes back decades. The company has for decades promoted its product as healthier,  
17 necessary for adequate nutrition, and the choice for the modern, sophisticated mother. Their  
18 advertising has at times attempted to portray breastfeeding as an inferior, less sophisticated  
19 choice.

20 25. The World Health Organization (WHO) and United Nation’s International  
21 Children’s Emergency Fund (UNICEF) held a meeting more than two decades ago to address the  
22 international marketing of breast-milk substitutes. The World Health Director concluded the  
23 meeting with the following statement: “In my opinion, the campaign against bottle-feed  
24 advertising is unbelievably more important than the fight against smoking advertisement.”  
25 Baumslag & Michels, 1995, p. 161. Recognizing the abuse and dangers of the marketing of infant  
26 formula, in 1981, the World Health Assembly (WHA) developed the International Code of  
27 Marketing of Breast-milk Substitutes (“the Code”), which required companies to acknowledge  
28 the superiority of breast milk, and prohibited any advertising or promotion of breast milk

1 substitutes to the general public. The Code specifically prohibited advertising in Article 5,  
 2 Section 1: “There should be no advertising or other form of promotion to the general public.” The  
 3 International Code of Marketing of Breast-milk Substitutes. Geneva: World Health Organization,  
 4 p.16 - 20 (1981).Defendant Abbott has acknowledged and pretended to endorse the Code: “We  
 5 support, educate and encourage mothers to breast-feed for as long as possible, including, where  
 6 possible, exclusive breast-feeding during the first six months of life and continued breastfeeding  
 7 up to and beyond two years of age. ... We acknowledge the importance of the World Health  
 8 Organization’s 1981 International Code of Marketing of Breast-Milk Substitutes ... and  
 9 subsequent World Health Assembly (WHA) resolutions. We respect the aim and principles of the  
 10 WHO Code to contribute to the provision of safe and adequate nutrition for infants, by: a) the  
 11 protection and promotion of breast-feeding; and b) ensuring the proper use of Breast-milk  
 12 Substitutes, when these are necessary, on the basis of adequate information and through  
 13 appropriate marketing and distribution.” Abbott Policy on the Marketing of Infant Formula.  
 14 [https://dam.abbott.com/en-](https://dam.abbott.com/en-us/documents/pdfs/transparency/Abbott_Policy_on_the_Marketing_of_Infant_Formula.pdf)

15 [us/documents/pdfs/transparency/Abbott\\_Policy\\_on\\_the\\_Marketing\\_of\\_Infant\\_Formula.pdf](https://dam.abbott.com/en-us/documents/pdfs/transparency/Abbott_Policy_on_the_Marketing_of_Infant_Formula.pdf)

16 26. Despite this assurance and warranty contained in its Policy, Defendant Abbott has  
 17 systematically violated the Code’s most important provision: “There should be no advertising or  
 18 other form of promotion to the general public.”

19 27. Notwithstanding the Code and Defendant Abbott’s own Policy claiming to  
 20 recognize the Code, advertising of cow-based infant formula like NeoSure has remained  
 21 pervasive in the United States until today. Abbott has paid lip service to the Code, but in actuality  
 22 has systematically violated its central provision.

23 28. The very name “Similac NeoSure” is deceptive, suggesting that NeoSure is *similar*  
 24 to *lactation*. Beginning with its brand name, Defendant Abbott has perpetuated the deception that  
 25 its product is on par with or similar to human milk.

26 29. “Since the late 19th Century, infant formula manufacturers have encouraged  
 27 mothers to substitute formula for breastmilk.” Rosenberg KD, Eastham CA, Kasehagen LJ,  
 28



Sandoval AP. Marketing infant formula through hospitals: the impact of commercial hospital discharge packs on breastfeeding. Am J Public Health. 2008;98(2):290-295.

30. For example, one author found an advertisement for a Similac product like NeoSure on the back cover of the April 2004 issue of American Baby Magazine, reproduced below, that made repeated comparisons of cow-based formula to breast milk; the ad used the phrase “like breastmilk” six times. Broussard Hyderkhan, A, Mammary malfunction: a comparison of breastfeeding and bottle feeding product ads with magazine article content, 2005.



Similac® Advance® can help develop both your baby's immune system and brain like breast milk.  
(Kisses, hugs, and silly songs are up to you.)

Breastfeeding is recommended for its many benefits. If you choose to feed formula, ask your doctor about Similac Advance.

Only Similac Advance with DHA and ARA has both\*:

- A patented blend of special breast milk nutrients called nucleotides, which has been clinically shown to help support the development of a baby's immune system like breast milk. *The clinical study showed immune cell development like breast milk. Whether this development provides immune protection like breast milk has not been shown. Breast milk also contains antibodies not found in infant formulas that are important for a baby's immune protection.*
- Published long-term clinical research showing brain development like breast milk.\*

So much like breast milk in so many ways.

\*Among formulas with DHA and ARA; infants studied at 12 and 39 months of age. ©2004 Abbott Laboratories.  
www.SimilacAdvance.com



1           31. In addition to perpetuating the myth that Similac products like NeoSure are “like  
2 breastmilk,” Defendant Abbott has also deceived the public into believing that physicians believe  
3 Similac products are an ideal choice for babies.

4           32. Beginning in 1989, Abbott began using claims in its advertising that Similac  
5 products like NeoSure were the “first choice of more physicians.”

6           33. A plain interpretation of this claim is that physicians believe Similac products like  
7 NeoSure are the “first choice” even in preference to breastmilk.

8           34. Beginning in 1995, Defendant Abbott began a heavy marketing campaign  
9 featuring the claim “1st choice of Doctors” on all its infant formula product labels, including  
10 NeoSure.

11           35. A marketing report commissioned by Defendant Abbott in March 1998  
12 summarized consumer reactions to several advertising pamphlets for Similac products. The “1st  
13 Choice of Doctors” claim scored highest in terms of consumers’ likelihood of purchase. The  
14 report concluded, “Doctor recommendations and the ‘science’ behind the formula appeared to  
15 drive purchase interest for this concept, as well as the other concepts tested.” Use of similar  
16 pieces emphasizing the same claim was “highly recommended.”

17           36. One study estimated that formula manufacturers spent \$4.48 billion on marketing  
18 and promotion in 2014. Baker, P, et al, Global trends and patterns of commercial milk-based  
19 formula sales: is an unprecedented infant and young child feeding transition underway? Public  
20 Health Nutrition, 2016.

21           37. One study found that direct-to-consumer advertising increased request rates of  
22 brand choices and the likelihood that physicians would prescribe those brands. Parker, R. S., &  
23 Pettijohn, C. E. (2003). Ethical considerations in the use of direct-to- consumer advertising and  
24 pharmaceutical promotions: The impact on pharmaceutical sales and physicians. Journal of  
25 Business Ethics, 48, 279-290.

26           38. One study found that exposure to infant feeding advertising has a negative effect  
27 on breastfeeding initiation. Merewood A, Grossman X, Chaudhuri J, Sadacharan R, Fein SB.  
28 Exposure to infant feeding advertising during pregnancy is associated with feeding decisions

1 postpartum. Paper presented at American Public Health Association 138th Annual Meeting &  
2 Exposition; November 2010; Washington, DC.

3 39. In a study on infant feeding advertisements in 87 issues of Parents magazine, a  
4 popular parenting magazine, from the years 1971 through 1999, content analysis showed that  
5 when the frequency of infant formula advertisements increased, the percentage change in  
6 breastfeeding rates reported the next year generally tended to decrease. Stang J, Hoss K, Story M.  
7 Health statements made in infant formula advertisements in pregnancy and early parenting  
8 magazines: a content analysis. *Infant Child Adolesc Nutr.* 2010;2(1):16-25.

9 40. The Stang study also found that infant formula company websites, printed  
10 materials, coupons, samples, toll-free infant feeding information lines, and labels may mislead  
11 consumers into purchasing a product that appears equivalent or superior to human milk. This may  
12 induce reliance on a biased source for infant feeding guidance. Stang J, Hoss K, Story M. Health  
13 statements made in infant formula advertisements in pregnancy and early parenting magazines: a  
14 content analysis. *Infant Child Adolesc Nutr.* 2010;2(1):16-25.

15 41. Defendant Abbott released an ad called “The Mother ’Hood” that frames the  
16 choice between breastmilk and Similac products like NeoSure as a matter of personal preference,  
17 a debate which, while heated, is ultimately conducted by parents who simply wish the best for all  
18 children. The advertising conceals the fact that the “debate” is a false one, manufactured by  
19 companies like Abbott for their own promotional purposes.  
20 [www.youtube.com/watch?v=JUbGHeZCxe4](http://www.youtube.com/watch?v=JUbGHeZCxe4).

21 42. Another advertisement by Defendant Abbott, titled “The Judgment Stops Here,” a  
22 documentary-style ad, likewise shows parents coming together, putting aside judgment of each  
23 other’s choices. The ad is deceptive, however, and violative of the Code and Abbott’s own  
24 marketing Policy, because it puts breast milk and formula on an even playing field, and attempts  
25 to chastise any opinion that the question is *not* merely one of personal choice and but clear  
26 scientific evidence. In other words, the ad attempts to insulate Similac products like NeoSure  
27 from criticism or judgment, when criticism is wholly appropriate from a scientific standpoint.  
28

1           43. Another ad by Defendant Abbott for a Similac product states, “[W]hen you are  
2 ready to turn to infant formula, but you don’t want to compromise, look to Pure Bliss by Similac.  
3 It’s modeled after breast milk.” [www.youtube.com/watch?v=kRaHiTMyYXs](http://www.youtube.com/watch?v=kRaHiTMyYXs).

4           44. Moreover, Defendant Abbott has also attempted to market its Similac products like  
5 NeoSure specifically to premature infants—the very children at highest risk from their use.

6           45. In 1978, Abbott began marketing “Similac 24 LBW” specifically for premature  
7 infants, claiming that the product was “introduced to meet the special needs of premature  
8 infants.”

9           46. In 1980, Abbott began marketing “Similac Special Care,” claiming it was the first  
10 low-birth-weight, premature infant formula with a composition designed to meet fetal accretion  
11 rates.

12           47. In 1988, Abbott began marketing “Similac Special Care With Iron,” claiming it  
13 “was the first iron-fortified formula for premature and low-birth-weight infants introduced in the  
14 US.”

15           48. As of 2016, Abbott marketed and sold seven products specifically targeting  
16 “Premature/Low birth-Weight Infants”:

17                   Liquid Protein Fortifier

18                   Similac NeoSure

19                   Similac Human Milk Fortifiers

20                   Similac Special Care 20

21                   Similac Special Care 24

22                   Similac Special Care 24 High Protein

23                   Similac Special Care 30

24           49. Defendant Abbott specifically targets parents of premature infants in its marketing.  
25 For example, a Google search for “feeding preemies formula” reveals among first-page results a  
26 paid advertisement for NeoSure, with the heading “For Babies Born Prematurely.” The ad states,  
27 “Your premature baby didn’t get her full 9 months in the womb, so her body is working hard to  
28 catch up. During her first full year, feed her Similac NeoSure, a nutrient-enriched formula for

1 babies who were born prematurely, and help support her development.” The advertisement  
2 further claims that NeoSure is “pediatrician recommended,” “#1 brand fed in Hospitals” and  
3 “backed by science.” The advertisement makes no reference to the specialized need pre-term  
4 infants have for human breast milk, and makes no mention of the risk of developing NEC.

5 50. At all relevant times, Defendant Abbott maintained “similac.com,” website  
6 directed at parents choosing formula products. The website states, “Need help choosing the right  
7 formula for your baby? Our Formula Finder can walk you through it.” The website includes the  
8 prompt, “Was your child born prematurely?” If the parent clicks “yes,” the website directs the  
9 parent to a page promoting NeoSure, [https://similac.com/formula-finder/baby-formula/similac-](https://similac.com/formula-finder/baby-formula/similac-expert-care-neosure-premature)  
10 [expert-care-neosure-premature](https://similac.com/formula-finder/baby-formula/similac-expert-care-neosure-premature). Through this website, Abbott directs parents of premature babies  
11 to use NeoSure. The page further claims that NeoSure is “[f]or babies who were born  
12 prematurely. Similac NeoSure supports excellent growth in premature babies’ gains in weight,  
13 length, and head circumference when compared to these gains in preterm babies fed term  
14 formulas.”

15 51. There is no mention of the risk of NEC. The website expressly and implicitly  
16 represents that NeoSure is safe for use with premature infants. This promotion is false and  
17 misleading.

18 52. A search for the following on Google returns paid advertisements by Defendant  
19 Abbott for NeoSure: (1) “Is formula healthy for premature infants?”; and (2) “Is formula safe for  
20 premature infants?” produces paid advertisements by Abbott for NeoSure.

21 53. Another advertisement by Defendant Abbott states “whether you choose to  
22 formula feed or, to supplement breast feeding with formula, you can be confident in the  
23 nourishment of Similac.” [www.similac.com/why-similac.html](http://www.similac.com/why-similac.html). The representation to parents that  
24 they can be “confident” is directly contradicted by studies that indicate the cow-based formula  
25 like NeoSure is dangerous to premature infants. The ad is false and misleading.

26 54. Defendant Abbott’s website also features reviews from parents whose premature  
27 infants were in the NICU, discussing how wonderful and safe the products are. There are no  
28

1 reviews discussing NEC. It is therefore likely that these reviews are curated by Abbott to present  
2 a misleading picture of unanimous endorsement of NeoSure.

3 55. CBS News reported that Defendant Abbott paid so-called “mommy bloggers” for  
4 positive reviews of Similac products like NeoSure. [https://www.cbsnews.com/news/abbott-pays-](https://www.cbsnews.com/news/abbott-pays-bloggers-for-positive-reviews-of-its-similac-app/)  
5 [bloggers-for-positive-reviews-of-its-similac-app/](https://www.cbsnews.com/news/abbott-pays-bloggers-for-positive-reviews-of-its-similac-app/)

6 56. Defendant Abbott has designed and implemented a systematic, powerful, and  
7 misleading marketing campaign to deceive parents into believing that: (1) cow-milk formula and  
8 fortifiers like NeoSure are safe; (2) cow-milk products like NeoSure are equivalent or even  
9 superior substitutes for breastmilk; (3) physicians consider cow-based products like NeoSure a  
10 first choice; (4) the decision to breastfeed or to use Similac products like Neosure is a matter of  
11 personal preference merely, with no objective scientific criteria; and (5) Similac products like  
12 NeoSure are necessary for the growth of and are perfectly safe for premature infants.

13 **C. Baby KM and Similac NeoSure**

14 57. Baby KM was born extremely prematurely at 23 weeks gestation on July 6, 2018,  
15 with a low birth weight of one pound, one ounce.

16 58. Baby KM was admitted to the NICU at Sunrise Hospital and Medical Center in  
17 Las Vegas, Nevada.

18 59. Following the birth, Baby KM was immediately fed NeoSure.

19 60. Baby KM then contracted life-threatening NEC that required three immediate  
20 surgeries. NEC has caused him to suffer failure to thrive, severe and ongoing developmental  
21 delays, difficult bowel movements, constipation, and significant suffering to this day.

22 61. Baby KM’s parents had no knowledge that NeoSure would increase the risk of  
23 their baby developing NEC.

24 62. As described above, Defendant Abbott promotes NeoSure on its website and in  
25 other media as a safe product, and one specifically needed by premature infants for adequate  
26 growth. [https://similac.com/baby-formula/](https://similac.com/baby-formula/similac-expert-care-neosure-premature) [similac-expert-care-neosure-premature](https://similac.com/baby-formula/similac-expert-care-neosure-premature). A link on this  
27 page claims that premature infants need NeoSure for “catchup growth”. <https://similac.com/baby->  
28

development/preemie/nutrition- premature-babies. A screenshot of both is captured on the following two pages.

63. This same webpage contains a video promoting NeoSure as a means to achieve adequate growth in premature infants.



### Preterm nutrition is a story of specialization



Since preterm babies start smaller, their "catch-up growth" will have to be faster than usual for the baby to become the same size as a full-term baby.

Babies born prematurely have specific nutritional needs throughout the first year as their bodies work hard to grow and develop. The right nutrition for premature babies helps them grow in ways you can see, such as weight, length, and head size. Nutrition is also vital for growth you can't see.

Whether you choose to breastfeed or use baby formula, after leaving the hospital, most preemies will benefit from nutritional supplementation or a specialized formula with nutrients that support brain, muscle, bone, and organ growth, and development of a strong immune system.

**Similac® NeoSure®** is clinically shown to help with catch-up growth. It supports excellent growth during baby's first year, providing increased protein, energy, vitamins, and minerals compared to term infant formula. This means extra calories for growth, as well as calcium and phosphorus for baby's growing bones.

The fat blend in Similac NeoSure is 25% medium-chain triglycerides, an easily digested and well-absorbed fat source.

**Similac NeoSure** supports better gains in weight, length, and head circumference when compared to standard infant formula.

Read more about the benefits of Similac NeoSure and our NEW value-size can. [Learn more](#)



**Similac® NeoSure®**

Promotes catch-up growth during your premature baby's first 12 months



Read all 464 reviews

Write a review

BUY NOW

Your premature baby didn't get her full 9 months in the womb, so her body is working hard to catch up. During her first full year, feed her Similac NeoSure, a nutrient-enriched<sup>†</sup> formula for babies who were born prematurely, and help support her development.

Similac NeoSure is now available in a NEW value-size can, which provides over 70% more formula.\*

**Supports excellent growth during baby's first year.<sup>1</sup>**

- Increased protein, energy, vitamins, and minerals compared to term infant formula
- Extra calories for growth<sup>†</sup>
- Calcium and phosphorus for baby's growing bones

Supports better gains in weight, length, and head circumference for premature babies when compared to term infant formula.<sup>1</sup> Has **OptiGRO®** to support your baby's brain and eye development.



Available In:



22.8-oz Powder



13.1-oz Powder



1-qt Ready to Feed



2-fl-oz Ready to Feed



NeoSure video



No Palm Oil/Palm Olein Oil

<https://similac.com/baby-formula/similac-expert-care-neosure-premature>.

64. This marketing is designed to instill confidence in Defendant Abbott's NeoSure, and to plant the seed in parents' minds that such formula is safe and necessary to the growth of a premature infant.

65. Prior to Baby KM being fed NeoSure, Plaintiffs were exposed to marketing from Defendant Abbott that NeoSure was safe and necessary to the growth and nutrition of their premature infant.

66. Although Defendant Abbott engages in an aggressive marketing campaign designed to make parents believe that NeoSure is safe and necessary for growth of a premature infant, the product is in fact highly dangerous to premature infants. NeoSure substantially increases the risk of NEC, as explained above.

67. NeoSure is commercially available at retail locations throughout Nevada and online for delivery to Nevada.

68. Despite knowing of the risk of NEC, Defendant Abbott did not warn parents of the risk of NEC associated with NeoSure.

69. Despite knowing of the risk of NEC, Defendant Abbott did not warn doctors, hospitals, or other healthcare providers of the risk of NEC associated with NeoSure.

70. The only warnings NeoSure contains are the following:

#### **Safety Precautions**

- **Never use a microwave oven to warm formula.** Serious burns can result.
- Powdered infant formulas are not sterile and should not be fed to premature infants or infants who might have immune problems unless directed and supervised by your baby's doctor.

<sup>\*</sup> Increased protein, vitamins, and minerals compared to term infant formula.

<sup>†</sup> Compared to infants fed a formula without DHA and ARA in a clinical trial with Similac Special Care and Similac NeoSure infant formulas with iron; prior to the addition of lutein.

<sup>‡</sup> Visual acuity measured at 4 and 6 months corrected age and assessed by VEP (visual evoked potential).

<sup>§</sup> Based on a subset of infants in a post-hoc analysis.

<sup>¶</sup> No significant difference has been shown between milk derived from rbST-treated and non-rbST-treated cows.

<sup>1</sup> Carver JD, et al. *Pediatrics* 2001;107:638-689.

<sup>2</sup> Groh-Wargo S, et al. *Pediatr Res* 2005;57:712-718.

<sup>3</sup> O'Connor DL, et al. *Pediatrics* 2001;108:359-371.

<sup>4</sup> Canfield LM, et al. *Eur J Nutr* 2003;42:133-141.

<sup>5</sup> Schweigert FJ, et al. *Eur J Nutr* 2004;43:39-44.

<sup>6</sup> Patton S, et al. *Lipids* 1990;25:159-165.

<sup>7</sup> Rubin LP, et al. *J Perinatol* 2012;32:418-424.

71. Despite knowing that NeoSure increases the risk of NEC, Defendant Abbott did not provide any instructions or guidance on how to avoid NEC.

72. Defendant Abbott failed to properly warn parents and healthcare providers that NeoSure can significantly increase the risk that a premature infant will develop NEC, failed to design said product such as to make it safe, and deceived the public, parents, physicians, and other healthcare providers into believing that NeoSure is a safe and necessary alternative to, supplement to, or substitute for human milk.

73. Despite knowing that NeoSure was being fed to premature infants without parents' informed consent, Defendant Abbott failed to require or recommend that hospitals inform parents of the significant risk of NEC, or to require that parents' informed consent be obtained prior to feeding it to preterm infants.

74. Defendant Abbott's cow-based formula NeoSure caused Baby KM to develop NEC, triggering severe intestinal disease and long-term adverse effects.

**FIRST CAUSE OF ACTION**

**(NEGLIGENT PRODUCTS LIABILITY)**

75. Plaintiffs incorporate by reference each of the preceding paragraphs as if fully set forth herein.

76. Prior to July 6, 2018, Defendant Abbott was aware, or should have been aware, that NeoSure was not safe for use in the premature infant, Baby KM, yet it took no steps to prevent its use in such a situation.

77. Defendant foresaw or should have foreseen that NeoSure would be used as it was in the case of Baby KM, and knew or should have known that such use would significantly increase the risk of NEC in Baby KM, yet it took no steps to prevent such use.

78. NeoSure was not safe to be used in the case of Baby KM and Defendant Abbott knew or should have known that NeoSure was unsafe to be fed to a preterm, low birth weight infant, yet it failed to provide any instructions or guidelines on when and how NeoSure would be safe to use in a premature infant like Baby KM.

79. Defendant Abbott has marketed NeoSure as safe and beneficial for premature infants like Baby KM.

80. Defendant Abbott has promoted NeoSure for extremely premature infants and claims NeoSure increases the baby's weight and caloric intake, and that NeoSure is more beneficial than harmful.

81. Defendant Abbott has advanced the false premises to parents, physicians, and other healthcare providers that human milk is not sufficient to meet the nutritional needs of premature infants, and that NeoSure is necessary as a substitute for or supplement to human milk.

82. Scientific research has unequivocally established the dangers of Defendant Abbott's cow-based product NeoSure in causing NEC in premature infants, yet Abbott did nothing to change its product, packaging, guidelines, instructions, or warnings.

83. Scientific studies show Defendant Abbott's NeoSure should not be sold for use in extremely premature infants, yet Abbott continued to market and sell NeoSure knowing it would

1 be used by infants like Baby KM and knowing NeoSure would significantly increase the risk of  
2 NEC in extremely premature infants like Baby KM.

3 84. Defendant Abbott knew or should have known that NeoSure would be used in the  
4 way it was used with Baby KM.

5 85. NeoSure's use was extremely dangerous and caused an unreasonably high risk that  
6 Baby KM would develop NEC, yet Defendant Abbott provided no detailed instructions or  
7 warnings to prevent or alter the way NeoSure was used.

8 86. Despite learning that NeoSure was linked to NEC, Defendant Abbott failed to  
9 properly collect data from doctors and hospitals in order to develop evidence based strategies,  
10 instructions, and warnings to reduce or prevent NeoSure from causing NEC.

11 87. Despite learning that NeoSure was linked to NEC, Defendant Abbott took no steps  
12 to determine whether and how that link was causal.

13 88. In the alternative, Defendant Abbott learned that NeoSure causes NEC in  
14 premature infants, yet did nothing to change its product, packaging, guidelines, instructions or  
15 warnings.

16 89. Despite knowing that NeoSure causes NEC in premature infants, Defendant  
17 Abbott did not conduct any testing, undertake to have others conduct testing and studies, or do  
18 any data analysis or research to determine when NeoSure should not be used or when and how  
19 NeoSure is safe for use.

20 90. Despite knowing that NeoSure causes NEC in premature infants, Defendant  
21 Abbott did not contact the FDA to inform the agency of this fact.

22 91. Baby KM's parents, physicians, and other healthcare providers were never told  
23 that NeoSure could cause Baby KM to develop NEC.

24 92. Baby KM's parents, physicians, and other healthcare providers were never told  
25 that NeoSure could and would cause Baby KM to suffer long term, devastating maladies, as Baby  
26 KM has and will.

27 93. Baby KM's parents, physicians, and other healthcare providers were not told of the  
28 studies showing cow-based formula like NeoSure was extremely dangerous to Baby KM.

1           94.     Baby KM's parents, physicians, and other healthcare providers were not told of the  
2 studies showing that human donor milk was safer for Baby KM than cow-based products like  
3 NeoSure.

4           95.     Baby KM's parents, physicians, and other healthcare providers were not told of the  
5 studies showing that an exclusive human milk diet is sufficient to meet all growth and nutritional  
6 goals of premature infants.

7           96.     Despite knowing that NeoSure causes NEC and long term adverse effects in  
8 premature infants, Defendant Abbott did not recommend or require discussion by hospitals,  
9 NICUs, or physicians of the risks of NEC and long term maladies with parents.

10          97.     Despite knowing that NeoSure causes NEC, as well as serious and devastating  
11 long term illnesses and adverse effects on growth and development, as it has in Baby KM,  
12 Defendant Abbott did not contact the FDA, NICUs, hospitals, or physicians to inform them that  
13 NeoSure is linked to or causes NEC and these long term consequences

14          98.     Defendant Abbott knew or should have known that its cow-based premature infant  
15 product NeoSure would be used, as it was, on extremely premature infants like Baby KM, yet it  
16 failed to properly warn hospitals, NICUs, doctors, parents, or consumers that NeoSure  
17 significantly increases the risk of NEC and long term adverse medical and developmental  
18 consequences in these babies; and is unsafe or contraindicated for extremely premature infants  
19 and low birth weight babies like Baby KM.

20          99.     Defendant Abbott's warnings and instructions for NeoSure are severely  
21 inadequate, vague, confusing, and provide a false sense of security in that they warn and instruct  
22 specifically on certain conditions, but do not warn that cow-based formula like NeoSure  
23 significantly increases the risk of NEC and its sequelae, nor provide any details on how to avoid  
24 such harm.

25          100.    Defendant Abbott failed to:

26               a.     provide a warning or instruction that parents need to be provided an  
27 informed choice between the safety of human milk versus the dangers of NeoSure;  
28

- b. provide proper instructions, guidelines, studies, or data on when and how to feed NeoSure to premature infants in order to decrease the risk of NEC;
- c. provide instructions to parents and physicians that NeoSure carries a significant risk of NEC and its long term sequelae;
- d. provide a prominent “black box”-type warning that NeoSure is known to significantly increase the risk of NEC and its sequelae when compared to human milk in premature infants and in low birth weight infants;
- e. provide well researched and well established studies linking cow-based products like NeoSure to NEC and its long term sequelae in premature infants and low birth weight infants;
- f. cite to or use up-to-date medical data on the proper and safe use of NeoSure;
- g. warn physicians and other healthcare providers of the extreme risk associated with feeding premature infants and low birth weight infants cow-based formula like NeoSure, which, had physicians and other healthcare providers known of it, would have induced physicians and other healthcare providers not to use NeoSure with Baby KM;
- h. send out “Dear Doctor” letters warning of the risks of NEC, and provide current scientific research and data to better guide hospitals and physicians to better care for the extremely premature infants;
- i. advise physicians and other healthcare providers that cow-based formula like NeoSure is not necessary to achieve growth and nutritional targets for premature infants;
- j. advise physicians and other healthcare providers that human milk is superior to cow-based products like NeoSure with regard to the overall health of a premature infant; and/or
- k. take adequate measures to warn despite knowing that parents were not being warned of the risk of NEC by their physicians.

101. Defendant Abbott’s massive marketing campaign as detailed in previous paragraphs has had the effect of: (1) diminishing the ability of parents to intelligently resist the



1 advice of a healthcare provider to give formula; (2) diminishing parents' desire and understanding  
2 of the importance of breastfeeding; (3) diminishing the relationship between physicians and  
3 patients relative to nutritional decision-making; (4) making it more difficult for a physician to  
4 persuade parents to breastfeed; and (5) making it easier and more economically viable for  
5 hospitals to feed premature infants instead of donor milk or human milk-derived fortifiers.

6 102. As a result of the inadequacy of the warnings and the pervasive marketing  
7 suggesting the safety and necessity of cow-based formula like NeoSure, Baby KM was fed  
8 NeoSure, which caused him to develop NEC and ultimately suffer significant long-term medical  
9 problems and developmental delays.

10 103. Defendant Abbott owed a duty of care to the children to whom NeoSure was  
11 targeted.

12 104. As a direct and proximate result of Defendant's Abbott's breach of duty in the  
13 design, development, manufacturing, labeling, advertising, and sale of NeoSure, Baby KM  
14 suffered severe medical injuries and long term damages that are yet to be determined. Baby KM's  
15 parents have expended and continue to expend significant sums for Baby KM's care and  
16 treatment.

17 105. NeoSure's defective design proximately caused Baby KM's NEC, and proximately  
18 caused Baby KM's long term medical and developmental problems.

19 **SECOND CAUSE OF ACTION**

20 **(STRICT PRODUCTS LIABILITY)**

21 106. Plaintiffs incorporate by reference each of the preceding paragraphs as if fully set  
22 forth herein.

23 107. Prior to July 6, 2018, Defendant Abbott was aware, or should have been aware,  
24 that NeoSure is not safe for use in premature infants like Baby KM, yet it took no steps to prevent  
25 its use in such a situation.

26 108. NeoSure was defectively designed as alleged above.

27 109. NeoSure is unreasonably dangerous as alleged above.  
28

110. Over the last several years, scientific data and well researched studies have concluded that cow-based products like NeoSure carry unreasonable risks of NEC, which far outweigh the products' benefits.

111. NeoSure's risk of causing NEC is extreme, and substantially deviates from consumers' and Plaintiffs' expectations.

112. Defendant Abbott failed to develop a human-based milk product that was safer for extremely premature infants and low birth weight infants like Baby KM.

113. As a result of NeoSure's defective design, Baby KM developed NEC and has continued to suffer long term problems and has needed multiple surgeries, treatments, and interventions, and will need them far into the future.

114. NeoSure's defective design proximately caused Baby KM's NEC, and proximately caused Baby KM's long term medical and developmental problems.

### **THIRD CAUSE OF ACTION**

#### **(NEGLIGENCE)**

115. Plaintiffs incorporate by reference each of the preceding paragraphs as if fully set forth herein.

116. Despite knowing that NeoSure significantly increases the risk of NEC in premature infants, Defendant Abbot was careless and negligent because it failed to:

- a. Collect data to determine if its products were safe for premature infants;
- b. Collect data to determine when and how its products could be used safely;
- c. Use the significant peer reviewed research to develop instructions and/or warnings on how and when NeoSure should be used in order to protect babies from NEC and its medical sequellae;
- d. Develop evidence-based guidelines or instructions to decrease the risk of NeoSure causing NEC;
- e. Provide evidence-based guidelines or instructions to decrease the risk of NeoSure causing NEC;

- f. Stop or deter NeoSure from being fed to extremely premature infants like Baby KM;
- g. Provide evidence-based guidelines or instructions on when or how an extremely premature infant like Baby KM should be transitioned to NeoSure;
- h. Continuously and vigorously study NeoSure to avoid NEC in premature infants;
- i. Send out letters with warnings to hospitals, NICUs, and doctors that NeoSure was significantly increasing the risk of NEC in premature infants like Baby KM;
- j. Send out letters with instructions to hospitals, NICUs, and doctors on when and how NeoSure should be used to avoid NEC;
- k. Market and/or sell its products in a way which would protect premature infants like Baby KM from NEC;
- l. Provide proper training or information to health care providers for safe use of NeoSure;
- m. Take reasonable precautions to prevent premature infants like Baby KM from developing NEC;
- n. Develop a human-milk-based premature infant formula;
- o. Properly or promptly notify the FDA that NeoSure significantly increases the risk of NEC in premature infants like Baby KM; and/or
- p. Require or recommend that hospitals warn of NeoSure's risk of causing NEC, despite knowing that NICUs and physicians were not warning of such.

117. Defendant Abbot's negligence proximately caused Baby KM's NEC, and proximately caused Baby KM's long-term medical problems and developmental delays.

**FOURTH CAUSE OF ACTION**  
**(NEGLIGENT MISREPRESENTATION)**

118. Plaintiffs incorporate by reference each of the preceding paragraphs as if fully set forth herein.

119. The allegations contained in previous paragraphs set forth specific representations Defendant Abbott has made to consumers, physicians, and other healthcare providers through its advertising and promotional materials (some of which are reproduced above). These representations were made by Abbott on an ongoing and repeated basis, and, as specifically relevant here, at various points between January 1, 2018, and July 2, 2018.

120. Defendant Abbott misrepresented that NeoSure was safe and beneficial for premature infants like Baby KM when it knew or should have known that NeoSure is unreasonably dangerous and causes NEC in premature infants and low birth weight infants like Baby KM.

121. Defendant Abbott misrepresented to parents, physicians, and other healthcare providers that cow-based products like NeoSure are necessary to the growth and nutrition of premature infants, when it knew or should have known that NeoSure is not necessary to achieve adequate growth.

122. Defendant Abbott misrepresented that NeoSure has no serious side effects, when it knew or should have known that it does.

123. Defendant Abbott negligently misrepresented that cow-based products like NeoSure are safe for premature infants like Baby KM.

124. Defendant Abbott negligently misrepresented that cow-based products like NeoSure are necessary for optimum infant growth.

125. Defendant negligently misrepresented that cow-based products like NeoSure are similar or equivalent to human milk.

126. Defendant Abbott's misrepresentations proximately caused Baby KM's NEC, and proximately caused Baby KM's long-term medical problems and developmental delays.

#### **FIFTH CAUSE OF ACTION**

#### **(DECEPTIVE TRADE PRACTICES)**

127. Plaintiffs incorporate by reference each of the preceding paragraphs as if fully set forth herein.

1           128. The allegations contained in previous paragraphs set forth specific representations  
2 Defendant Abbott has made to consumers, physicians, and other healthcare providers through its  
3 advertising and promotional materials (some of which are reproduced above). These  
4 representations were made by Abbott on an ongoing and repeated basis, and, as specifically  
5 relevant here, at various points between January 1, 2018, and July 2, 2018.

6           129. Defendant Abbott willfully ignored or avoided the recent scientific data and  
7 studies concluding that NeoSure causes NEC so that it could continue to profit from the sale of  
8 NeoSure.

9           130. Defendant Abbott willfully failed to take protective measures it knew would save  
10 premature infants like Baby KM from developing NEC, and suffering long-term medical and  
11 developmental problems as a result.

12           131. The acts, omissions, and practices of Defendant Abbott alleged herein constitute  
13 deceptive trade practices within the meaning of Nev. Rev. Stat. §§ 598.0915 and 598.0925.  
14 Plaintiffs have standing to bring these claims because they have suffered and lost money as a  
15 result of Abbott's deceptive trade practices.

16           132. Defendant Abbott has engaged in deceptive trade practices by making  
17 misrepresentations as alleged above.

18           133. Defendant Abbott engaged in deceptive trade practices by and through:

19           a. Developing a systematic, pervasive, effective, and manipulative marketing  
20 scheme designed to make parents believe that cow-based products like NeoSure are as safe, or  
21 even safer, than human milk, specifically as to premature infants like Baby KM;

22           b. Purporting to support the Code while actually undermining and disobeying  
23 its key provisions;

24           c. Advertising, promotion, and marketing that induced parents of premature  
25 infants not to breastfeed by disparaging breastfeeding, placing its cow-based products like  
26 NeoSure on an equivalent level, and marketing "personal choice" as a substitute for sound  
27 medical judgment;  
28

1 d. Concealing the risks of NEC associated with the use of NeoSure by  
2 premature infants like Baby KM;

3 e. Representing that NeoSure has characteristics, ingredients, uses, or benefits  
4 it does not have;

5 f. Engaging in fraudulent or deceptive conduct that creates a likelihood of  
6 confusion or misunderstanding;

7 g. Expending enormous amounts of money on political lobbying, political  
8 involvement, “donations” to hospitals, and medical associations—all designed to protect  
9 Defendant Abbott’s financial interests, motivated by profit, and in direct conflict with societal  
10 interests—ensuring that regulators do not publicize the dangers of formula like NeoSure versus  
11 breastmilk, ensuring that direct advertising of infant formula is not prohibited in the United  
12 States, and preventing federal regulation of formula;

13 h. Intentionally marketing breastfeeding parents as unappealing, in order to  
14 disparage breastfeeding and promote NeoSure;

15 i. Paying online reviewers, especially so-called “mommy bloggers,” to give  
16 positive reviews of NeoSure, when Defendant Abbott knew this would induce parents to buy  
17 NeoSure;

18 j. Making monetary contributions to endear itself to the medical profession  
19 and win its favor; and/or

20 k. Marketing campaigns that created an environment where parents would  
21 resist medical advice to breastfeed.

22 134. Defendant Abbott intended for parents and healthcare providers to rely on its  
23 representations and advertisements regarding NeoSure so that Abbott would profit from its sale.  
24 Abbott has spent millions of dollars in promotion, advertising, lobbying, gifts, and “charitable  
25 donations”—all designed to maintain an image that NeoSure is safe and effective, despite  
26 knowing the opposite to be true, and to secure profits in an incredibly lucrative industry.



1           135. Despite publicly expressing a commitment to breastfeeding, Defendant Abbott  
2 designed and executed promotional campaigns that discourage breastfeeding, allowing Abbott to  
3 capture greater market share and earn greater profits.

4           136. As a result of the deceptive trade practices engaged in by Defendant Abbott, Baby  
5 KM's parents paid and will have to pay large sums of money to care for and treat Baby KM. The  
6 cumulative effect of Abbott's conduct directed at parents and healthcare providers has been to  
7 create demand for and sell NeoSure. Each aspect of Abbott's conduct combined to artificially  
8 create sales of NeoSure, and to deceive the public at large and Baby KM's parents in particular.

9           137. Defendant Abbott is under a duty to refrain from deceptive acts or practices in the  
10 design, labeling, development, manufacture, promotion, and sale of NeoSure.

11           138. Had Defendant Abbott not engaged in the deceptive conduct described above,  
12 Baby KM would not have been fed the dangerous product, and would not have incurred related  
13 injuries and damages.

14           139. Defendant Abbott's intentional, deceptive, unconscionable, immoral, and  
15 fraudulent representations and material omissions to Baby KM's parents, physicians, and  
16 consumers constitute deceptive trade practices.

17           140. Defendant Abbott violated Nevada law intended to protect consumers against  
18 deceptive trade and business practices and false advertising, by knowingly and falsely  
19 representing that NeoSure is fit to be used for the purpose for which it is intended, when in fact it  
20 is defective and dangerous. These representations were made in marketing and promotional  
21 materials.

22           141. Defendant Abbott had actual knowledge of the defective and dangerous condition  
23 of NeoSure and failed to take any action to cure such defective and dangerous conditions.

24           142. Baby KM's physicians and healthcare providers relied upon Defendant Abbott's  
25 misrepresentations and omissions in deciding to use NeoSure.

26           143. Baby KM's parents were misled into not objecting to the use of NeoSure as a  
27 result of Defendant Abbott's misrepresentations, omissions, and deceptive marketing campaigns.  
28

**PRAYER FOR RELIEF**

144. Plaintiffs seek a judgment awarding:

- a. Compensatory damages in an amount to be determined at trial;
- b. Punitive damages in an amount to be determined at trial;
- c. Attorneys' fees and costs of suit; and
- d. All other relief the Court finds just and proper.

**DEMAND FOR JURY TRIAL**

145. Plaintiffs demand a jury trial on all issues so triable.

Dated: February 12, 2022

Respectfully submitted,

LEGAL OFFICES OF JAMES J. LEE

By: /s/ James J. Lee

James J. Lee, Esq. (Nevada Bar No. 1909)  
james@leelitigate.com  
2620 Regatta Drive #102  
Las Vegas, NV 89128  
Telephone: 702.521.4377 (cell)  
Telephone: 702.664.6545 (office)  
Facsimile: 702.946.1115

Wendy R. Fleishman (NY Bar No. WF 3017)  
(*pro hac vice anticipated*)  
wfleishman@lchb.com  
LIEFF CABRASER HEIMANN & BERNSTEIN, LLP  
250 Hudson Street, 8th Floor  
New York, NY 10013-1413  
Telephone: 212.355.9500  
Facsimile: 212.355.9592

Fabrice N. Vincent (CA Bar No. 160780)  
fvincent@lchb.com  
(*pro hac vice anticipated*)  
Lexi J. Hazam (CA Bar No. 224457)  
lhazam@lchb.com  
(*pro hac vice anticipated*)  
LIEFF CABRASER HEIMANN & BERNSTEIN, LLP  
275 Battery Street, 29th Floor  
San Francisco, CA 94111-3339  
Telephone: 415.956.1000  
Facsimile: 415.956.1008

*Attorneys for Plaintiffs*

1 Dated: February 12, 2022

2  
3 2373266.6

4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28